



PTO/SB/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/625,116
	Filing Date	July 22, 2003
	First Named Inventor	Jolidon, et al.
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	21229 US

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks -References B1 to B3, and C1 to C10		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Kimberly J. Prior
Signature	
Date	October 16, 2003

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date <u>October 16, 2003</u>			
Typed or printed	Kimberly J. Prior		
Signature		Date	October 16, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s): Jolidon, et al.

Serial No. 10/625,116, filed July 22, 2003
(Ref. No. 21229 US)

For: **2,3-DIHYDRO-ISOINDOL-1-ONE DERIVATIVES**

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
October 16, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.


Documents B1 to B3, and C1 to C10, listed on Form PTO-1449 are enclosed.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/625,116
Filed: July 22, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Kimberly J. Prior", is written over a horizontal line.

Attorney for Applicant(s)

Kimberly J. Prior

(Reg. No. 41,483)

340 Kingsland Street

Nutley, New Jersey 07110

Telephone: (973) 235-6208

Telefax: (973) 235-2363



Substitute for form 1449A/PTO				Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Application Number	10/625,116		
				Filing Date	July 22, 2003		
				First Name Inventor	Jolidon, et al.		
Sheet	1	of	1	Attorney Docket Number	21229 US		
U.S. PATENT DOCUMENTS							
Examiner Initials'	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
	A						
FOREIGN PATENT DOCUMENTS							
Examiner Initials'	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	B1	WO 01/34172			Vela Pharmaceuticals Inc.	05/17/2001	
	B2	WO 97/33572			Somerset Pharmaceuticals Inc.	09/18/1997	
	B3	WO 96/40095			Harris, Richard, Y.	12/19/1996	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials'	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	Bach et al., Proc. Natl. Acad. Sci. USA 85:4934-4938 (July, 1988)	
	C2	Cesura & Pletscher, Prog. Drug Research 38:171-297 (1992)	
	C3	Fowler et al., J. Neural. Transm. 49:1-20 (1980)	
	C4	M. S. Benedetti et al., Biochem. Pharmacol. 38:555-561 (1989)	
	C5	Saura et al., Neuroscience 70:755-774 (1996)	
	C6	Bentué-Ferrer et al., in CNS Drugs 6:217-236 (1996)	
	C7	Gardner et al., J. Clin. Psychiatry 57(3): 99-104 (1996)	
	C8	Schlaeger & Christensen, Cytotechnology 30: 71-83 (1999)	
	C9	Zhou & Panchuk-Voloshina, Analytical Biochemistry 253: 169-174 (1997)	
	C10	Grethe et al., J. Org. Chem. 33: 494-503 (1968)	

Examiner Signature		Date Considered
-----------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

135222